Physician profile

Steven Lichtenstein

Gastroenterology (Internal Medicine) · Darby, PA

NPI 1518942002

$27,039.61

in general payments reported to CMS, 2019-2025

36 companies · $1,827 in 2025

The $1,827 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$6,020.75
Food and Beverage$5,367.37
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program$2,875.00
Education$28.06

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Takeda Pharmaceuticals U.S.A., INC. $6,558.96 2019-2025 Gattex, Entyvio
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $5,100.15 2019-2025 Trulance, Xifaxan, Plenvu
Olympus Medical Systems Corporation $4,865.75 2024
Olympus Corporation $3,570.00 2021-2023
Abbvie INC. $2,579.47 2019-2025
Janssen Biotech, INC. $995.48 2019-2025 Stelara, Tremfya, Simponi
Braintree Laboratories, INC. $469.24 2019-2025 Suflave, Sutab
Celgene Corporation $369.65 2022-2024 Zeposia
Ardelyx, INC. $367.24 2023-2025 Ibsrela
Cook Medical LLC $277.82 2019-2025 Hemospray
Qol Medical, LLC $234.18 2024-2025 Sucraid, Sucraid
Aimmune Therapeutics, INC. $174.85 2024-2025 Zenpep
Madrigal Pharmaceuticals $165.00 2024-2025 Rezdiffra, Resmetirom
Janssen Scientific Affairs, LLC $143.63 2024 Tremfya
Gilead Sciences, INC. $132.66 2023-2025
Show all 36 companies
CompanyGeneral paymentsYearsTop products
Covidien LP $125.74 2019
Pfizer INC. $123.33 2019-2025
Merck Sharp & Dohme LLC $118.74 2019-2024 Dificid
Laborie Medical Technologies Corp. $91.88 2023
Exact Sciences Corporation $63.24 2023-2024 Cologuard Collection Kit
Nestle Healthcare Nutrition INC. $57.32 2021-2022
Olympus America INC. $57.29 2025 Single Use Repositionable Clip
Redhill Biopharma INC. $56.19 2020-2021
Ironwood Pharmaceuticals, INC $48.94 2019-2020
Celltrion USA INC. $47.42 2024 Zymfentra, Vegzelma
Phathom Pharmaceuticals, INC. $43.69 2024-2025 Voquezna
Cumberland Pharmaceuticals, INC. $39.01 2024 Kristalose
Evoke Pharma, INC. $29.67 2023-2024 Gimoti
Siemens Medical Solutions USA, INC. $22.83 2024 Acuson Sequoia Diagnostic Ultrasound System
Fresenius Kabi USA, LLC $19.05 2024 Idacio
Novo Nordisk INC $19.03 2019
Regeneron Healthcare Solutions, INC. $18.06 2023 Dupixent
Ferring Pharmaceuticals INC. $14.64 2019
Capsovision, INC. $14.24 2025 Capsocam Plus
Boston Scientific Corporation $13.80 2024 Dreamwire
Allergan, INC. $11.42 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Steven Lichtenstein

$27,039.61

in general payments reported 2019-2025

Years
2019-2025
Top company
Takeda Pharmaceuticals U.S.A., INC.
Context
The $1,827 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).

https://glasscript.com/doctor/205132/steven-lichtenstein

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.